Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment (Q85059501)

From Wikidata

Jump to navigation Jump to search

scientific article published on September 21, 2010

Language	Label	Description	Also known as
English	Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment	scientific article published on September 21, 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

based on heuristic

inferred from title

Hartmut Goldschmidt

6

object named as

Hartmut Goldschmidt

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Ulrike Klein

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Kai Neben

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Thomas Hielscher

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Christiane Heiss

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Anthony D. Ho

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20857112

17 July 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20857112

17 July 2024

publication date

21 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

full work available at URL

https://hal.archives-ouvertes.fr/hal-00583544/file/PEER_stage2_10.1007%252Fs00277-010-1080-4.pdf

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20857112

17 July 2024

http://link.springer.com/content/pdf/10.1007/s00277-010-1080-4.pdf

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

http://link.springer.com/article/10.1007/s00277-010-1080-4/fulltext.html

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

http://link.springer.com/content/pdf/10.1007/s00277-010-1080-4

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

Annals of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

90

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

429-439

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Improved survival in multiple myeloma and the impact of novel therapies

1

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies

2

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group

4

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

5

91

1555

author name string

MS Raab

publication date

2006

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure

6

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

Renal failure in multiple myeloma: incidence, correlations, and prognostic significance

7

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies

8

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

Endocytosis of light chains induces cytokines through activation of NF-kappaB in human proximal tubule cells

10

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

Cytotoxicity of myeloma light chains in cultured human kidney proximal tubule cells.

11

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party

13

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents

14

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors

15

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis

16

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.

17

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

18

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

19

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

20

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

International uniform response criteria for multiple myeloma.

22

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data

23

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study

24

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

25

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

26

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

27

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment

28

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

29

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

A phase 2 study of bortezomib in relapsed, refractory myeloma

30

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

31

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

A Proportional Hazards Model for the Subdistribution of a Competing Risk

32

1 reference

10.1007/S00277-010-1080-4

https://api.crossref.org/works/10.1007/S00277-010-1080-4

17 July 2024

Identifiers

10.1007/S00277-010-1080-4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857112%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q85059501&oldid=2206392156"